Skip to main content
TipRanks
Go Ultimate75% OFF

Immuron Limited (ANW) AI Stock Analysis

1 Followers
DE:ANW

Immuron Limited

(Frankfurt:ANW)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthRevenue scaling over several years indicates improving commercial traction and growing adoption of Immuron’s products. A larger revenue base can support operating leverage, broaden market presence, and provide a stronger platform for future investment in the company’s immunotherapy portfolio.
Negative Factors
Persistent LossesContinued operating and net losses show that the current revenue base is not yet sufficient to cover the company’s cost structure. Although losses appear to be narrowing, the absence of sustained profitability limits internal funding capacity and leaves the business exposed to prolonged earnings pressure.

Immuron Limited (ANW) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%40%DE:ANW-42.86%EWG+4.05%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 7.25M
Dividend Yield
―
Average Volume (3M)
8,854
Price to Earnings (P/E)
-2.9
Beta (1Y)
-0.43
Revenue Growth
2.87%
EPS Growth
46.27%
Country
Germany
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Immuron Limited Business Overview & Revenue Model

Company Description

Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Research and De...

Immuron Limited Risk Analysis

Immuron Limited disclosed 62 risk factors in its most recent earnings report. Immuron Limited reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks
1.If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, the price of our ordinary shares and ADSs could decline significantly and raising capital could be more difficult.Q2, 2024
2.A material breach in security relating to the Company's information systems and regulation related to such breaches, cyber-attacks, or other disruptions could adversely affect the Company, expose us to liability and affect our business and reputation.Q2, 2024

Immuron Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:ANW against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:BIOAU:BIO63NeutralAUD 79.84M20.1946.74%―29.68%1520.00%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:AVEAU:AVE49NeutralAUD 42.50M-7.33-211.39%―-46.59%9.09%
AU:ANRAU:ANR44NeutralAUD 2.53M-2.35-101.34%――64.58%
AU:EZZAU:EZZ42NeutralAUD 13.64M-2.56-20.36%13.76%-30.79%-177.68%
AU:AGNAU:AGN40UnderperformAUD 12.85M-7.08-29.22%――81.00%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%DE:ANWAU:AVEAU:ANRAU:AGNAU:EZZAU:BIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:ANW and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:ANWImmuron Limited0.02-0.01-38.46%
AU:AVEAvecho Biotechnology Limited0.010.0010.00%
AU:ANRAnatara Lifesciences Ltd0.010.000.00%
AU:AGNArgenica Therapeutics Ltd0.10-0.13-55.56%
AU:EZZEZZ Life Science Holdings Ltd.0.29-2.09-87.82%
AU:BIOBiome Australia Ltd0.34-0.07-15.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.